Notably, overexpression of DLL3 was associated with shorter overall survival (OS) in endometrial cancer (Wang et al., 2018), ovarian cancer (Jia et al., 2019), breast cancer (Yuan et al., 2021) and small-cell bladder cancer (Koshkin et al., 2019). The gene discussed is DLL3; the disease is urinary bladder small cell neuroendocrine carcinoma.